Coya Therapeutics Highlights Treg Function Innovations at Upcoming Evercore Health Conference

Coya Therapeutics Enhances Focus on Treg Function at Upcoming Health Conference

Coya Therapeutics, Inc., a clinical-stage biotechnology company based in Houston, is set to showcase its innovative work in enhancing regulatory T cell (Treg) function at the 7th Annual Evercore HealthCONx Conference scheduled for December 3 to 5, 2024. The company’s participation highlights its commitment to addressing chronic inflammation and immune dysregulation, which are central to various systemic and neuroinflammatory conditions. Coya's CEO, Dr. Arun Swaminathan, and Executive Chairman, Dr. Howard Berman, will engage in a fireside chat moderated by Michael DiFiore from Evercore ISI on December 3 at 12:55 PM ET. This discussion is expected to provide valuable insights into the company's strategic direction and ongoing projects aimed at treating complex diseases.

Coya Therapeutics focuses on developing therapies that specifically target dysfunctional Tregs, which play a critical role in maintaining immune homeostasis. The company’s pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Notably, its lead investigational product, COYA 302, represents a significant advancement in the field. COYA 302 combines a low-dose IL-2 and CTLA4-Ig for subcutaneous administration, employing a unique dual mechanism of action. This therapy aims to treat neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease by enhancing Treg numbers and functions. This approach not only targets the underlying causes of inflammation but also seeks to restore immune balance more effectively than traditional therapies.

The potential impact of Coya’s multi-targeted therapeutic strategy is profound, particularly in the context of diseases characterized by chronic inflammation and immune dysregulation. By reducing activated microglia and pro-inflammatory mediator secretion, COYA 302 could offer a novel solution for patients suffering from these debilitating conditions. As Coya prepares for the upcoming conference, stakeholders and the medical community are encouraged to engage in the conversation about the future of Treg-enhancing therapies and their role in combating systemic and neuroinflammatory diseases.

In addition to the live discussions, Coya Therapeutics will offer opportunities for one-on-one meetings throughout the event, allowing investors and collaborators to explore potential partnerships and insights into the company’s innovative research. Stakeholders can also access an archived webcast of the presentation on Coya’s website for further details, ensuring that the company's advancements in Treg functionality are widely disseminated and understood in the biopharmaceutical landscape.